Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC

Mar 30, 2021
Supplements And Featured PublicationsThe Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung CancerVolume 1Issue 1

Antoinette Wozniak, MD, FACP, FASCO, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer.

Antoinette Wozniak, MD, FACP, FASCO, a visiting professor of medicine and associate director of clinical research at the University of Pittsburgh Medical Center (UPMC), as well as the director of the Lung Cancer Disease Unit and co-director of the UPMC Lung Cancer Center of Excellence, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer (NSCLC).

Many ongoing research efforts are examining which patients are most likely to benefit from immunotherapy, according to Wozniak. This is important, as many patients with NSCLC who are treated with this modality may not achieve clinical benefit, Wozniak says.

Another area of focus is identifying why some patients do not respond to treatment, or stop responding entirely, as well as whether utilizing 2 immunotherapy agents that target 2 different pathways will be useful in overcoming mechanisms of resistance or acquired resistance. The field hopes to answer these questions in the coming years, Wozniak concludes.

Related Videos
View All
Related Content